Walk into almost any fertility clinic today even one marketed as the Best IVF Centre in its region and, alongside the standard IVF protocol, you’ll likely be offered a menu of optional extras: endometrial scratching, embryo glue, time-lapse imaging, immune therapies, PGT-A genetic screening, acupuncture, and more. These “add-ons” can increase the cost of a single IVF cycle by hundreds or even thousands of dollars but how many of them actually improve the odds of having a baby? This is a look at what the evidence really says, and why the gap between marketing and science has become one of the most quietly controversial issues in fertility medicine.
Why Add-Ons Exist
IVF is expensive, emotionally taxing, and doesn’t always work on the first try. That combination creates a powerful incentive on both sides: patients are often willing to try almost anything that might improve their chances, and clinics operate in a competitive, largely private-pay market where offering the latest technology can be a selling point. Many add-ons are approved for use meaning they’re safe without being proven to actually increase live birth rates, which are the outcome that matters most.
This distinction between “approved” and “proven effective” is where much of the controversy lives.
What the Evidence Actually Shows
Independent reviews, most notably the UK’s Human Fertilisation and Embryology Authority (HFEA), which rates common add-ons using a traffic-light system based on the quality of supporting evidence have found that the large majority of popular add-ons lack robust evidence of benefit for the average patient.
A few examples:
- Endometrial scratching (a minor procedure thought to improve implantation) was once widely offered, but larger, more rigorous trials have found little to no benefit for most patients.
- Time-lapse imaging (continuous embryo monitoring) can give embryologists more data, but evidence that it improves live birth rates over standard incubation remains limited.
- PGT-A (preimplantation genetic testing for aneuploidy), which screens embryos for chromosomal abnormalities before transfer, is genuinely useful in specific situations for instance, for some patients with recurrent miscarriage or advanced maternal age but its benefit for the general IVF population is still debated, and it doesn’t guarantee a healthy pregnancy.
- “Embryo glue” (a culture medium used during transfer) has shown mixed results across studies, with some suggesting a modest benefit and others finding none.
- Immune therapies (such as intralipid infusions or steroids intended to modulate the immune system) are among the most scientifically contested add-ons, with little consistent evidence they improve outcomes, and some carry their own risks.
None of this means these interventions are useless in every case; some may genuinely help specific patients with specific diagnoses. The concern raised by regulators and researchers is that they are frequently marketed broadly, to patients who may not be the ones most likely to benefit.
The Economics of Hope
What makes this issue distinct from ordinary medical overtreatment is the emotional context. People pursuing IVF are often at a point of significant vulnerability having tried for a long time to conceive, facing a ticking biological clock, or having already been through failed cycles. In that state, the promise of even a small edge can feel worth almost any price. Clinics aren’t necessarily acting in bad faith; many genuinely believe in the interventions they offer, and the science in this field moves quickly. But the asymmetry of information between clinic and patient means it can be difficult for someone outside the field to know which recommendations are backed by strong data and which are, at best, promising but unproven.
What This Means for Patients
Some practical takeaways that fertility advocates and independent bodies commonly recommend:
- Ask for the evidence, not just the theory. A reasonable question for any add-on is: “What does the data show for someone with my specific diagnosis?” rather than “Could this help?” A leading IVF specialist should be able to answer this with specific data, not just reassurance.
- Check independent ratings where available. Resources like the HFEA’s add-on ratings (for UK patients) offer a rare independent look at the evidence base, though similar centralized resources are less standardized in other countries.
- Look beyond marketing labels. A clinic calling itself the Best IVF Centre in its city or country isn’t a substitute for checking its actual published success rates and evidence-based practices.
- Consider cost relative to benefit. An add-on that costs relatively little and carries no meaningful risk may be a reasonable choice even with modest evidence. One that adds thousands of dollars with uncertain benefit deserves more scrutiny.
- Remember that “newer” isn’t automatically “better.” Novel technology sometimes represents real progress, and sometimes represents a good story that hasn’t yet been tested rigorously.
A Field Still Catching Up to Itself
The IVF add-on debate reflects a broader tension in reproductive medicine: the science of assisted reproduction has advanced rapidly, but the infrastructure for rigorously testing every new refinement hasn’t always kept pace with the enthusiasm for offering it. As more countries and professional bodies push for standardized, transparent evidence reporting, patients may eventually have clearer guidance. Until then, an informed, question-asking approach paired with a candid conversation with a leading IVF specialist remains one of the most effective tools a patient has, right alongside the science itself.
